Cite
HARVARD Citation
Short, N. et al. (n.d.). A phase II study of omacetaxine mepesuccinate for patients with higher‐risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents. American journal of hematology. 94 (1), pp. 74-79. [Online].